Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 4/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.43 |
| ▸ | F12 | P00748 | 2/20 | 0.42 |
| ▸ | F7 | P08709 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27828047 | 0.85 | CYP2C9 (0.53) | F2CYP2C9CYP2C19ALDH1A1CYP3A4 | |
| SCHEMBL6924316 | 0.85 | P2RX7 (0.48) | F2TSHRALDH1A1EPHX2SETDB1 | |
| SCHEMBL5654926 | 0.84 | HPGD (0.48) | F2ALDH1A1PRSS1 | |
| SCHEMBL7109335 | 0.82 | KCNH2 (0.46) | ALDH1A1SETDB1 | |
| SCHEMBL7564251 | 0.82 | ALDH1A1 (0.43) | TSHRALDH1A1EPHX2SETDB1 | |
| SCHEMBL19716939 | 0.81 | EPHX2 (0.48) | TSHRALDH1A1CYP3A4EPHX2 | |
| SCHEMBL20957065 | 0.81 | NOS2 (0.43) | CYP2C9TSHRCYP2C19ALDH1A1CYP3A4 | |
| SCHEMBL5968658 | 0.81 | NPC1 (0.47) | F2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL697972 | 0.81 | ALDH1A1 (0.63) | TSHRALDH1A1EPHX2 | |
| SCHEMBL3557506 | 0.81 | P2RX7 (0.53) | F2TSHRALDH1A1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922535-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-2830624-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150038498-A1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME LLC | 2015-02-05 | — | — | US | disclosed |
| EP-2830624-A1 | THROMBIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2014025658-A1 | PYRROLIDINE THROMBIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2013148478-A1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030158218-A1 | Thrombin inhibitors | NANTERMET PHILIPPE G (US) | 2003-08-21 | — | — | US | disclosed |
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002057225-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315141-A1 | Thrombin Inhibitors | F3, F2, F9 | F2 2/4885CYP1A2 1056/4885CYP2D6 1392/4885 |
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | F2 2/4885CYP1A2 2628/4885CYP2D6 3676/4885 |
| US-20030158218-A1 | Thrombin inhibitors | F2, SERPINC1, TFPI | F2 1/4885CYP1A2 1407/4885CYP2D6 3679/4885 |
| US-20150038498-A1 | THROMBIN INHIBITORS | F3, F2, CFH | F2 2/4885CYP1A2 1679/4885CYP2D6 1015/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | F2 1/4885CYP1A2 1203/4885CYP2D6 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.